| ICD-9-CM: |
| 011 - | Pulmonary Tuberculosis |
| 011.0 - | Tuberculosis of Lung, Infiltrative |
| 011.1 - | Tuberculosis of Lung, Nodular |
| 011.2 - | Tuberculosis of Lung with Cavitation |
| 011.3 - | Tuberculosis of Bronchus |
| 011.8 - | Pulmonary Tuberculosis, Other Specified Type |
| 011.9 - | Pulmonary Tuberculous, Unspecified; Respiratory Tuberculosis, NOS; Tuberculosis of Lung, NOS |
| 012 - | Tuberculosis, Respiratory, Other |
| 012.2 - | Isolated Tracheal or Bronchial Tuberculosis |
| 012.8 - | Respiratory Tuberculosis, Other Specified; Tuberculosis of Mediastinum, Nasopharynx, Nose (Septum), Sinus, Any Nasal |
| 137 - | Late Effects of Tuberculosis |
| 137.0 - | Late Effects of Respiratory or Unspecified Tuberculosis |
Tuberculosis (TB) is a chronic infection of the lungs caused by the bacterium Mycobacterium tuberculosis. It is contagious and can be very difficult to treat. The disease is spread through airborne droplets expelled from an infected individual's mouth through coughing, sneezing, or spitting.
If the bacterium is inhaled, the lungs respond by walling off the infected area in nodules known as tubercles. Visible upon x-ray, this stage of TB is termed primary tuberculosis, and for most individuals, the immune system stops the disease here. However, a tenth of these individuals progress to an active TB infection (Agrawal). An active infection occurs when the bacteria spread from the original site into the blood or lymph systems, then move to other areas where they cause infection (extrapulmonary tuberculosis). Although most common in the lung, TB infections can also occur in the skin, kidneys, bones, reproductive and urinary systems.
Although the body's immune system tries to control the infection instead of being destroyed, the bacteria may instead become inactive (dormant). At a later time (perhaps years), if the individual's immune system becomes impaired (due to leukemia, lymphoma, cancer, steroid therapy, radiation treatment, or infection with certain viruses, including HIV, bacteria, or fungi), the dormant bacteria may become active.Risk: TB is more common in men and blacks. Miliary TB mostly affects patients aged 65 years and older (Lessnau). Native Americans are more likely to develop TB. TB and lung cancer have been identified as comorbid diagnoses in 5% of cases, but whether having TB alone increases the risk of cancer has not been clearly documented (Agrawal).
Since 1985, however, the number of TB cases has increased. Reasons for this increase include the HIV/AIDS epidemic, increased numbers of immigrants from countries where TB is prevalent, increased poverty, illicit drug use, poor compliance with treatment programs, and more individuals residing in nursing homes. Incidence and Prevalence: Roughly 15 million patients have TB in the US; annually less than 0.1% of patients have cavitary smears that are positive for TB (Agrawal). Approximately 10% of all infected patients are likely to develop reactivation of TB with the highest risk of doing so occurring within the first 2 years of primary infection (Agrawal). At one time, TB was the leading cause of death in the US, but improvements in hygiene, nutrition, and medical care during the early part of the twentieth century dramatically reduced the incidence of TB. Worldwide 1.5% of TB patients have the miliary form (Lessnau). In other parts of the world, 19% to 43% of people have TB with or without any symptoms with an annual incidence rate of roughly 4% (Agrawal). |
Source: Medical Disability Advisor
History: Individuals with early symptoms may report fatigue, weight loss, fever, night sweats, and loss of appetite. As the disease progresses, there may be chest pain with a productive cough. Sputum also increases and may eventually be streaked with blood (hemoptysis). Shortness of breath may indicate damage in the lungs. Physical exam: Individuals with TB are often chronically ill, but may present with only minimal signs and symptoms. Chest sounds may be abnormal, especially over the upper lobes of the lungs. Weight loss and muscle wasting ("consumption") may be present. Tests: A tuberculin skin test (Mantoux test) is used to identify individuals infected with the TB bacteria 6 to 8 weeks after exposure. A positive test, however, does not indicate that the individual has active TB, only that there has been an infection by the bacteria sometime in the past. Because this test can report false negative with a recent infection (less than 2 to 3 months previously) or in immunocompromised individuals (HIV), it should be repeated if a person has recent exposure to TB. Once the individual has had a positive skin test, further skin testing is not recommended due to skin damage at the reaction site. Those with a positive skin test should be tested by chest x-ray.
An x-ray identifies the characteristic lesions in the lungs and may also reveal fluid in the pleural space (pleural effusion) or an enlarged heart (pericarditis). An x-ray of the kidneys using injected dye outlines the kidneys, revealing abnormal masses or cavities that may be caused by TB. A chest CT is a better test than a chest x-ray and has increased sensitivity and specificity. Ultrasound can be helpful in imaging the liver. Head CT and MRI can reveal lesions in the brain that are infected with TB.
To confirm the diagnosis, a culture is used to identify the TB bacteria. Material for culture may include a sample of material expelled from the lungs (sputum), infected fluid drawn from the chest, abdomen, joint, or around the heart, or a small piece of infected tissue (biopsy). Because TB bacteria grow very slowly, this culture can take up to 4 weeks. Cultures are also used in sensitivity tests to determine what drugs will best combat the bacteria. A polymerase chain reaction (PCR) may be performed on a sample of spinal cord fluid to identify tuberculous meningitis. Tuberculosis of the female reproductive organs may be identified through examination of the pelvis using a laparoscope or from scrapings inside the uterus.
Newer and more rapid DNA tests are beginning to be used for diagnosis. These tests use techniques that amplify the tuberculosis bacterial DNA and can speed the time for diagnosis to 2 days.
Individuals with TB should also be tested for HIV infection since TB often occurs early in the course of HIV infection. People who have come into close contact with the patient, such as spouse and family members, need tuberculin skin testing. If their close contacts have a positive skin test, a chest x-ray is indicated to rule out the spread of disease to the lungs. |
Source: Medical Disability Advisor
Because the emergence of drug-resistant strains of TB bacteria has made treatment difficult, the disease is typically treated with a combination of antibiotics, such as, isoniazid and rifampin for 6 to 12 months and pyrazinamide and ethambutol for 2 months. Although individuals with pulmonary TB are usually not contagious after 10 to 14 days of drug therapy, treatment should be continued for 3 months after sputum cultures are negative for the TB bacteria.
More resistant strains of TB are treated for 18 to 24 months with more powerful antibiotics that have more serious side effects. Successful treatment requires cooperation between the individual and health care providers. Individual compliance is a problem with TB treatment due to the side effects of the drugs. For example, isoniazid and rifampin can cause hepatitis, and ethambutol can cause vision problems. If an individual does not complete treatment, the cure rate decreases, and there is an increased risk of reactivation of disease and development of drug-resistant TB.
In order to prevent the development of active TB, treatment can be given to individuals in close contact with infected individuals and to those with a positive skin test. Individuals with active TB need to take precautions to prevent the spread of the disease by properly covering their mouths and noses when they cough and sneeze and by washing their hands.
Although a vaccine for TB is available, it is not widely used in the US, as its effectiveness is not known. |
Source: Medical Disability Advisor
With appropriate antibiotic therapy, only 10% of patients will die (Lessnau). Individuals with pulmonary TB are usually not contagious after 10 to 14 days of drug treatment. However, a follow-up sputum analysis should be performed to make sure there is no longer any danger of transmission. Treatment should be continued for 3 months after sputum cultures are negative for the TB bacteria. Drugs used to treat TB however, have many side effects and should be constantly monitored.
Relapse of TB often occurs as a result of noncompliance with treatment. With complete and proper treatment, relapse rates are less than 5% (Lessnau).
Individuals infected with resistant strains of TB have a lower cure rate. Strains of TB bacteria resistant to two or more drugs (multidrug-resistant) can have a higher reported mortality rate. |
Source: Medical Disability Advisor
Physical and respiratory therapy applied in conjunction with medications can be important in the overall treatment of the individual with TB. Physical therapy improves ventilation through breathing exercises localized to the area of lung involvement and then followed by a gradual strengthening program. When tolerated, an exercise that promotes both relaxation and a postural alteration for the muscles that aid in breathing begins with the individual assuming a relaxed sitting position while leaning forward and resting the forearms on the thighs or a pillow in the lap. This position is held for up to 15 to 20 minutes.
When hospitalized, the physical therapist and/or respiratory therapist help the individual cough in order to mobilize secretions and clear the airway by having the individual lie in a position that allows for the most effective drainage of secretions. The individual may lie on his or her side with the affected side upward and the head slightly lower than the chest. In addition to proper positioning, the physical therapist uses percussion and vibration techniques to the affected areas to help "shake loose" mucous and secretions. The therapist performs chest percussion with the hands in a cupped position, mildly striking repeatedly over the area of the lung affected by TB.
Once medications are effective, the symptoms of TB subside, and breathing becomes easier, focus is then placed on strength and endurance by incorporating aerobic-type activity into the rehabilitation program. By building endurance, the individual increases the ability to work and the resistance to fatigue. A physical therapist experienced in cardiac and pulmonary rehabilitation keeps a daily log of the individual's blood pressure, heart rate, and cardiac rhythm. As endurance increases without symptoms of shortness of breath, the individual begins active upper and lower extremity exercises using very light resistance in addition to light aerobic activities such as brisk walking and low-resistance biking.
The individual with TB is told that the exercise program can be a lengthy process in order to obtain the maximum benefit of increased pulmonary stamina. Because most individuals with TB are managed with medication, it is important that they let the rehabilitation personnel know what medications they are taking as many of these drugs alter the acute and chronic response to exercise. During the course of rehabilitation, the individual is reminded that a full course of therapy is necessary to kill all the bacteria. Failure to properly complete treatment can create drug-resistant strains of the disease that may render the treatment ineffective. |
Source: Medical Disability Advisor
| Complications of TB may include collapsed lung and abscess in the lymph nodes. TB that has spread outside the lungs (extrapulmonary tuberculosis) commonly affects the kidney, bones, and joints (tuberculous arthritis). The infection may spread to the prostate, seminal vesicles, and epididymis in men, and to the peritoneum (tuberculous peritonitis) in women. Scarring of the ovaries and fallopian tubes can cause sterility. TB can spread to the heart (tuberculous pericarditis) or the base of the brain (tuberculous meningitis). Delayed treatment can result in irreparable brain damage. Tuberculous meningitis can also result in a brain tumor (tuberculoma). |
Source: Medical Disability Advisor
| Individuals with pulmonary TB are usually not contagious after 10 to 14 days of drug treatment. However, a follow-up sputum analysis should be performed to make sure there is no longer any danger of transmission. Decreased lung capacity may make strenuous activity difficult. Significant loss of vital organ function due to secondary or opportunistic infections may lengthen disability or require permanent accommodations. |
Source: Medical Disability Advisor
| If an individual fails to recover within the expected maximum duration period, the reader may wish to consider the following questions to better understand the specifics of an individual's medical case. Regarding diagnosis:
- Were symptoms such as fatigue, weight loss, fever, night sweats, loss of appetite, chest pain, or a productive cough present?
-
Does individual have a history of past infection or recent exposure to tuberculosis?
-
Does individual have underlying immune suppression (i.e., HIV, leukemia, lymphoma, cancer, steroid or radiation treatment)?
-
Did individual have a positive Mantoux test? Was the diagnosis confirmed with a sputum culture?
-
Were additional diagnostic tests done to rule out other organ involvement?
-
If the diagnosis is uncertain, were other conditions with similar symptoms (i.e., other lung infections, sarcoidosis, or lung cancer) ruled out?
Regarding treatment:
- Did individual receive prompt diagnosis and appropriate antibiotic therapy?
-
Has individual been compliant with antibiotic treatment regimen?
-
Has individual undergone follow-up cultures to verify effectiveness of treatment?
-
Has individual experienced any side effects from the medication?
-
Has individual stopped taking medication because of side effects? If so, what alternatives are available?
-
Does individual fully understand the importance of completing the whole course of medication?
Regarding prognosis:
- Based on the severity of symptoms, the type of treatment required, and the general health of individual, what was the expected outcome?
-
Has adequate time elapsed for recovery?
-
Has individual completed the full course of medications?
-
Have repeat cultures been done to determine if there is drug resistance? Have appropriate changes been made in the medications?
-
Does individual have an underlying condition (HIV or other immune suppressing condition) that may impact ability to recover?
|
Source: Medical Disability Advisor
| CitedAgrawal, Anjali, and Anurag Agrawal. "Lung, Postprimary Tuberculosis." eMedicine. Eds. Judith K. Amorosa, et al. 5 Nov. 2004. Medscape. 26 Oct. 2004 <http://emedicine.com/radio/topic412.htm>.Lessnau, Klaus-Dieter, and Cynthia de Luise. "Miliary Tuberculosis." eMedicine. Eds. Joseph Richard Masci, et al. 5 Nov. 2004. Medscape. 26 Oct. 2004 <http://emedicine.com/med/topic1476.htm>. |
Source: Medical Disability Advisor
| Feedback |
| Send us comments, suggestions, corrections, or anything you would like us to hear. If you are not logged in, you must
include your email address, in order for us to respond. We cannot, unfortunately, respond to every comment.
If you are seeking medical advice, please contact your physician. Thank you! |
Send this comment to:
Sales
Customer Support
Content Development
|
|
| |
|
|
|
|
|
This publication is designed to provide accurate and authoritative information in
regard to the subject matter covered. It is published with the understanding that
the author, editors, and publisher are not engaged in rendering medical, legal,
accounting or other professional service. If medical, legal, or other expert assistance
is required, the service of a competent professional should be sought. We are unable to respond to requests for advice.
Any Sales inquiries should include an email address or other means of
communication.
|